Radius Health Presents New Data on Osteoporosis Treatment at World Congress

Radius Pharmaceuticals, Inc., introduced new real-world data at the 24th Edition of the World Congress on Osteoporosis, showing that TYMLOS (abaloparatide) demonstrated lower incidence of hip and non-vertebral fractures compared to teriparatide in postmenopausal women over 50. This analysis utilized data from a large cohort of 43,352 women, comparing outcomes over an 18-month treatment period.

Results indicated a hip fracture occurrence of 1.1% in the abaloparatide group versus 1.4% in the teriparatide group. Nonvertebral fractures were also lower in the abaloparatide cohort, reported at 4.4% compared to 5.0% in those treated with teriparatide. Major cardiovascular events were similar between groups, suggesting a favorable balance in safety profiles.

The study was conducted using data from the Symphony Health Patient Source and the Osteoporosis Patient Transactional Datasets, focusing on new patients to anabolic therapy from May 2017 to December 2021. Propensity score matching was employed to balance patient characteristics across treatment groups.

According to Dr. Felicia Cosman, this evidence bolsters the efficacy and safety profile of TYMLOS, providing valuable insights for clinical decision-making in osteoporosis management. The study conclusions were shared during an oral presentation at the congress held in London, aiming to guide better treatment approaches in clinical settings.